Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Quest Diagnostics Incorporated
Type
Public
Traded as NYSE: DGX
S&P 500 Component
Industry Health care
Founded New York City, United States (1967)
Founder Paul Brown
Headquarters Madison, New Jersey, United States
Area served
United States, Brazil, Mexico, United Kingdom, India
Key people
Steve Rusckowski (CEO)
Revenue IncreaseUS$7.5 Billion (2015)
Operating income
IncreaseUS$1.4 Billion (2015)
Net income
IncreaseUS$0.7 Billion(2015)
Total assets IncreaseUS$10.0 Billion(2015)
Total equity IncreaseUS$4.7 Billion (2015)
Number of employees
44,000 (2015)
Website questdiagnostics.com

Quest Diagnostics Incorporated is a Fortune 500 American company providing clinical laboratory services with headquarters in Secaucus, New Jersey. Founded in 1967 as Metropolitan Pathology Laboratory, Inc., it became an independent corporation with the Quest name on December 31, 1996. In addition to the United States, Quest Diagnostics also runs operations in United Kingdom, Mexico, Brazil, Puerto Rico and a laboratory in India and also has collaborative agreements internationally with various hospitals and clinics. The company has approximately 44,000 employees, generates more than $7 billion in revenue and offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease and neurological disorders.

Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical lab for manufacturing and distributing a faulty product. In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state’s Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.

Investment goal date:
Dividends reinvested
Quest Diagnostics Incorporated DGX report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-04-21
--
--
Q4 2017
2018-01-24
--
--
Q3 2017
2017-10-19
1.3900
1.1500
Q2 2017
2017-07-25
1.5500
1.3700
Q1 2017
2017-04-20
1.3300
1.1600
Q4 2016
2017-01-26
1.3100
1.0900
Q3 2016
2016-10-20
1.3700
1.3400
Q2 2016
2016-07-21
1.3400
1.3700
Q1 2016
2016-04-21
1.1200
0.7000
Q4 2015
2016-01-28
1.1900
1.2900
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Allianz Asset Management AG
2036839
AMERICAN CENTURY COMPANIES INC
2132929
BESSEMER GROUP INC
2459254
BLACKROCK ADVISORS LLC
4408708
BlackRock Fund Advisors
3248788
BlackRock Inc.
15362418
BlackRock Institutional Trust Company, N.A.
4370095
Capital International Investors
2090000
DIMENSIONAL FUND ADVISORS LP
2022107
LSV ASSET MANAGEMENT
3150309
MACQUARIE GROUP LTD
8363911
NORTHERN TRUST CORP
2126054
SCHRODER INVESTMENT MANAGEMENT GROUP
2188114
STATE STREET CORP
6918900
Vanguard Group, Inc
13504122
Major Shareholders
Name Relationship
Total Shares
Holding stocks
WILENSKY GAIL R
0.0200% (24960)
DGX / UNH /
PFEIFFER GARY M
0.0100% (15534)
DGX / INAP / SZYM /
BRITELL JENNE K
0.0100% (21476)
CCK / DGX / URI /
RUSCKOWSKI STEPHEN H
0.1200% (166116)
COV / DGX / XRX /
MAIN TIMOTHY L
0.0100% (14691)
DGX / JBL /
RING TIMOTHY M
0.0100% (14585)
BCR / DGX /
STANZIONE DANIEL
0.0200% (34675)
DGX / INAP /
ORDONEZ KATHY
0.0100% (9569)
DGX / PACB /
BUEHLER WILLIAM F
0.0200% (26225)
DGX /
ZIEGLER JOHN B
0.0100% (16557)
DGX /
BONGIORNO THOMAS F
0.0100% (11837)
DGX / EVHC /
HAGEMANN ROBERT
0.0900% (126722)
DGX / GPK / R / ZMH /
PREVOZNIK MICHAEL E
0.0300% (40327)
DGX /
BALDWIN JOHN C MD
0.0100% (12949)
DGX /
Cohen Jon R
0.0500% (70683)
DGX /
GUINAN MARK
0.0300% (49917)
DGX / HRC /
Gregg Vicky B
0.0100% (8525)
ACHC / DGX / FHN / TMH /
Doherty Catherine T.
0.0500% (69415)
DGX /
Haydon John B.
0.0100% (19890)
DGX /
Cunningham Everett
0.0300% (39052)
DGX /
Davis J. E.
0.0300% (37543)
DGX /
% ()